Navigation Links
Access Pharmaceuticals CEO Interviewed on Financial Website
Date:6/25/2009

Call Offered Executive Summary and Perspective on Business Strategy

DALLAS, June 25 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Mr. Jeffrey Davis, Chief Executive Officer and Mr. David Luci, Director and Consultant, were recently interviewed by StocksHaven.com, a financial website. The hour-long call was to provide an executive summary, along with an overview and update of the Access Pharmaceuticals's business strategy. Mr. Davis shed light on acquisitions, partnerships, current and future plans, and also discussed preparations to re-rejoin a major exchange. The interview is currently featured on the website at http://www.stockshaven.com/.

"We are pleased to be featured by StocksHaven Investments," commented Mr. Davis. "As we continue to build upon our business, now is an opportune time to learn about Access and we are glad to share our exciting investment thesis with financial websites that offer investors new and upcoming investment ideas."

About StocksHaven.com

StocksHaven.com is a website which hosts services for StocksHaven Investments. The website contains a blog, free level 2 quotes, discussion forum, stock research reports, conference calls, investment dictionary, news feeds, videos, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; and Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
2. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
3. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
4. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
5. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
6. Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care
7. Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
8. Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
9. Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
10. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
11. New organic material may speed Internet access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. β€œIn further expanding our ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):